Miles Wang, a researcher at OpenAI, is leaving the company to launch a new startup focused on using artificial intelligence to accelerate drug discovery. Wang is in talks to raise approximately $200 million at a $2 billion valuation, with venture capital firm Lightspeed in discussions to lead the funding round. Several other OpenAI researchers are expected to join the new venture, signaling growing momentum in the competitive field of AI-powered pharmaceutical development.

Why Is This Startup Different From Other AI Drug Discovery Companies?

Wang's startup may be working on AI models designed to identify new uses for existing drugs and potentially revive medications that previously failed in clinical trials. This approach differs from building drugs from scratch because FDA-approved medications have already undergone safety testing. Finding new applications for these drugs can significantly reduce the time to market and lower development costs compared to traditional drug discovery pathways.

The timing of Wang's departure reflects intense investor interest in applying AI to life sciences breakthroughs. Just days before the announcement, Chai Discovery, a two-year-old startup developing AI models to predict molecular interactions and identify new drugs, announced a $400 million funding round at a $3.8 billion valuation. Similarly, Isomorphic Labs, a spinoff from Google DeepMind that also develops AI models for drug discovery, raised $2.1 billion in its Series B round in May.

Who Is Miles Wang and What Is His Background?

Wang joined OpenAI in 2024 after leaving Harvard, where he was pursuing a bachelor's degree in computer science. At OpenAI, he co-authored research papers evaluating how AI models can automate and accelerate scientific discovery. His departure reflects a broader trend of young, accomplished technologists launching startups directly from major AI labs, with investors increasingly comfortable backing founders who have not completed traditional college degrees.

How to Understand the Competitive Landscape in AI Drug Discovery

• Market Momentum: Multiple well-funded startups are racing to apply AI to drug discovery, with valuations exceeding $2 billion becoming common in the space.
• Investor Confidence: Major venture capital firms like Lightspeed are leading funding rounds, signaling strong belief in the commercial viability of AI-driven pharmaceutical development.
• Talent Migration: Experienced researchers from leading AI labs like OpenAI and Google DeepMind are launching their own companies, bringing cutting-edge expertise to the startup ecosystem.

The emergence of Wang's startup underscores a fundamental shift in how the pharmaceutical industry approaches drug development. Rather than relying solely on traditional laboratory methods and clinical trials, companies are increasingly leveraging machine learning models to accelerate the discovery process. These AI systems can analyze vast amounts of biological and chemical data to identify promising drug candidates far faster than conventional approaches.

Wang's focus on repurposing existing drugs represents a pragmatic strategy within this broader trend. By targeting medications already approved by the FDA, his startup can bypass some of the lengthy regulatory hurdles that typically delay new drug launches. This approach has proven successful in the past; many blockbuster medications were originally developed for different conditions than those they now treat.

The funding discussions remain ongoing, and Wang disputed some details reported about the valuation and company structure, though he did not specify the correct figures. Regardless of the final terms, the announcement reflects the intense competition among AI researchers and entrepreneurs to capture value in the life sciences sector. As more startups emerge from major AI labs, the race to develop transformative AI-powered drug discovery platforms is likely to accelerate further.